FIRST AMENDMENT TO THE LICENSE AGREEMENT OF FEBRUARY 1, 2005 BETWEEN COLUMBIA AND OMNIMMUNE CORP. March 29, 2005 Harris A. Lichtenstein, Ph.D. President and CEO Omnimmune Corp.
Exhibit
10.9
COLUMBIA
UNIVERSITY SCIENCE AND TECHNOLOGY VENTURES
FIRST
AMENDMENT TO THE LICENSE AGREEMENT OF
FEBRUARY
1, ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ AND OMNIMMUNE CORP.
March 29,
2005
▇▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇▇▇▇▇, Ph.D.
President
and CEO
Omnimmune Corp.
▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇
▇▇▇▇▇
▇▇▇
▇▇▇▇▇▇▇,
▇▇▇▇▇ ▇▇▇▇▇
Dear
▇▇▇▇▇▇:
The
Agreement between Omnimmune Corp. and The Trustees of Columbia University in the
City of New York, dated February 1, 2005 (“Agreement”),
is hereby amended as follows:
|
1.
|
Section
17 (a) is amended to read as
follows:
|
a. This
Agreement shall be effective as of the date first recited above and shall
continue in full force and effect until its expiration or termination in
accordance with this Section 17; provided however that if the Stock Purchase
Agreement or the Stockholders Agreement involving Columbia and
Omnimmune is not fully executed within 120 days of the effective date of
this Agreement, then this Agreement is null and void.
All other
terms and conditions of the Agreement shall remain in full force and
effect, except as expressly amended herein.
Please
indicate your agreement to the Letter Amendment by signing where indicated
below, and returning one original signed Letter to my attention.
Very
truly yours,
/s/
▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇
▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇
Senior
Director
Science
and Technology Ventures
The
Trustees of Columbia University in the City of New York
AGREED
AND ACKNOWLEDGED:
OMNIMMUNE
CORP.
By:/s/ ▇▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇▇▇▇▇▇
President
& CEO
Date:3/29/05